ID   Ben-Men-1-LucB
AC   CVCL_JK01
DR   Wikidata; Q54796000
RX   PubMed=23151902;
RX   PubMed=25596744;
CC   Sequence variation: Mutation; HGNC; HGNC:7773; NF2; Simple; p.Leu214fs*6 (c.640delC); Zygosity=Hemizygous (PubMed=23151902).
CC   Genetic integration: Method=Transduction; Gene=HGNC; HGNC:11730; TERT.
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P08659; Firefly luciferase.
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: In situ; Brain, falx cerebri; UBERON=UBERON_0006059.
DI   NCIt; C4329; Meningothelial meningioma
DI   ORDO; Orphanet_2495; Meningioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1959 ! Ben-Men-1
SX   Female
AG   68Y
CA   Telomerase immortalized cell line
DT   Created: 15-05-17; Last updated: 19-12-24; Version: 12
//
RX   PubMed=23151902; DOI=10.1158/0008-5472.CAN-12-1888; PMCID=PMC3549000;
RA   Burns S.S., Akhmametyeva E.M., Oblinger J.L., Bush M.L., Huang J.,
RA   Senner V., Chen C.-S., Jacob A., Welling D.B., Chang L.-S.;
RT   "Histone deacetylase inhibitor AR-42 differentially affects cell-cycle
RT   transit in meningeal and meningioma cells, potently inhibiting
RT   NF2-deficient meningioma growth.";
RL   Cancer Res. 73:792-803(2013).
//
RX   PubMed=25596744; DOI=10.18632/oncotarget.2810; PMCID=PMC4385830;
RA   Chow H.-Y., Dong B., Duron S.G., Campbell D.A., Ong C.C.,
RA   Hoeflich K.P., Chang L.-S., Welling D.B., Yang Z.-J., Chernoff J.;
RT   "Group I Paks as therapeutic targets in NF2-deficient meningioma.";
RL   Oncotarget 6:1981-1994(2015).
//